Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi

Jaguar has received the initial $16M payment related to the company's recently executed US out-license agreement for Mytesi ® ...
Cochrane

What are the benefits and risks of oils given by mouth (enteral lipids) in infants who either have or are at risk of liver disease due to intestinal failure?

There were no studies that specifically studied the effect of enteral lipids in infants at risk of liver disease or who have liver disease due to prolonged need for artificial nutrition secondary to ...
Kaleido Scope

Intestinal Rehab Program

Intestinal failure is defined as having an intestinal condition which renders a child unable to maintain adequate hydration and meet calorie absorption needs sufficient for growth. This results in ...
Morningstar

Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal ...

SBS-IF is the second orphan disease target indication for Jaguar's intestinal failure program, which includes microvillus inclusion disease (MVID) - for which the company completed a meeting in ...
The Indianapolis Star

Jaguar Health Provides Updates on Orphan Disease Intestinal Failure Development Program for Crofelemer

Enrollment in company’s first-of-its-kind placebo-controlled Phase 2 study to evaluate the efficacy of crofelemer for microvillus inclusion disease (MVID) in pediatric patients has reached ...

Jaguar Health, Inc.: Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi

Jaguar has received the initial $16M payment related to the company's recently executed US out-license agreement for Mytesi and Canalevia-CA1, which has the potential to provide Jaguar up to an additi ...